Free Trial

BioLargo Q2 2023 Earnings Report

BioLargo logo
$0.29 +0.00 (+0.73%)
As of 03:37 PM Eastern

BioLargo EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

BioLargo Revenue Results

Actual Revenue
$1.45 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioLargo Announcement Details

Quarter
Q2 2023
Time
N/A

BioLargo Earnings Headlines

BioLargo provides 2025 corporate outlook
WARNING: “Buffett Indicator” flashing for first time in 50 years
Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
Contrasting BioLargo (NASDAQ:BLGO) & Ashland (NYSE:ASH)
BioLargo CEO Dennis Calvert appoints to Department of Commerce’s ETTAC
See More BioLargo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioLargo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioLargo and other key companies, straight to your email.

About BioLargo

BioLargo (NASDAQ:BLGO) invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per - and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.

View BioLargo Profile

More Earnings Resources from MarketBeat